ArticleChemistryOpen2026
Development of a Sustainable Biocatalytic Process for Geranyl Benzoate Production Using Immobilized Lipase.
Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The demand for sustainable and natural alternatives in the flavor and fragrance industries has driven interest toward enzymatic synthetic routes. This study reports the enzymatic production of geranyl benzoate, a monoterpenoid ester with potential bioactivity and commercial applications, catalyzed by immobilized lipases using a solvent-free system. A central composite design was employed to optimize the key process variables: molar ratio, temperature, and enzyme loading using Lipozyme 435 as the biocatalyst. Under optimal conditions (1:7 molar ratio, 80°C, 30% enzyme), a high geraniol conversion (72%) was achieved within 6 hr, as validated by a predictive model. The study also investigated the inhibitory effects of coproduced methanol, demonstrating that open-reactor systems (enabling methanol evaporation) enhanced conversion (>99% in 48 h) compared to closed systems. Additionally, substrate-exposure experiments highlighted methyl benzoate's inhibitory effect on Lipozyme 435, reducing its activity by 54%, whereas Lipura Flex showed greater resilience. Reusability tests indicated a decline in enzyme performance, with Lipozyme 435 retaining 22% activity after five cycles. Cell tests demonstrated no cytotoxicity and proliferative effect at high concentrations. These findings highlight the potential of solvent-free enzymatic processes for sustainable production of geranyl benzoate and provide insights into operational challenges, including methanol management and biocatalyst stability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.